Corrigendum: Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. TheJournal of gastrointestinal oncology · 2024
   Article
2. CEACAM1 is a direct SOX10 target and inhibits melanoma immune infiltration and stemness.iScience · 2022
   Article
3. Single-Cell Proteomics Preparation for Mass Spectrometry Analysis Using Freeze-Heat Lysis and an Isobaric Carrier.Journal of visualized experiments : JoVE · 2022
   Article
4. DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype.JCI insight · 2022
   Article
5. The State of Melanoma: Emergent Challenges and Opportunities.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
   Article

Corrections and comments

• Erratum for
  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.2017

Authors and funding

17 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract